Kiromic develops biomarker- and small molecule-based diagnostic and therapeutic programs for solid tumors and hematologic malignancies.
Kiromic Biopharma has raised $8.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2022.
Kiromic Biopharma is headquartered in Houston, United States.
Kiromic develops biomarker- and small molecule-based diagnostic and therapeutic programs for solid tumors and hematologic malignancies.
Kiromic Biopharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kiromic Biopharma — Funding & Investors." VCBacked, October 27, 2022, https://www.vcbacked.co/company/kiromic-biopharma. Accessed August 14, 2026.
VCBacked. (2022). Kiromic Biopharma — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/kiromic-biopharma
{{cite web |title=Kiromic Biopharma — Funding & Investors |url=https://www.vcbacked.co/company/kiromic-biopharma |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated